loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 75679 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 MYLAN (3)

filter

01 CAPSULE, EXTENDED RELEASE;ORAL (3)

filter

01 DISCN (2)

02 RX (1)

filter

01 KETOPROFEN (3)

filter

01 No (3)

URL Supplier Web Content
CAPSULE, EXTENDED ...
200MG
2002-02-20
75679
KETOPROFEN
RX
No
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
CAPSULE, EXTENDED ...
150MG
2002-02-20
75679
KETOPROFEN
DISCN
No
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
CAPSULE, EXTENDED ...
100MG
2002-02-20
75679
KETOPROFEN
DISCN
No
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 75679

Looking for FDA Orange Book APPLICATION 75679 3

19

Viatris, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

One of their notable products is KETOPROFEN, with a corresponding application number 75679.

Regulatory Information RX

With a dosage strength 200MG

Dosage Form Route CAPSULE, EXTENDED RELEASE; ORAL

Reference Listed Drug No

Approved since 2002-02-20

18

Viatris, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

One of their notable products is KETOPROFEN, with a corresponding application number 75679.

Regulatory Information DISCN

With a dosage strength 150MG

Dosage Form Route CAPSULE, EXTENDED RELEASE; ORAL

Reference Listed Drug No

Approved since 2002-02-20

17

Viatris, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

One of their notable products is KETOPROFEN, with a corresponding application number 75679.

Regulatory Information DISCN

With a dosage strength 100MG

Dosage Form Route CAPSULE, EXTENDED RELEASE; ORAL

Reference Listed Drug No

Approved since 2002-02-20

Post Enquiry
POST ENQUIRY